Skip to Main Content

1,258

Views

0

CrossRef citations to date

0

Altmetric

Oncology

The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective

Vladislav Berdunova PHMR Ltd, London, UKCorrespondence[email protected]

https://orcid.org/0000-0002-5743-2184 View further author information

,

Ewan Lawsa PHMR Ltd, London, UK

https://orcid.org/0000-0001-6088-2787 View further author information

,

Gebra Cuyun Carterb Exact Sciences, Redwood City, CA, USAView further author information

,

Roger Luob Exact Sciences, Redwood City, CA, USAView further author information

,

Christy Russellb Exact Sciences, Redwood City, CA, USAView further author information

,

Sara Campbellb Exact Sciences, Redwood City, CA, USAView further author information

,

Jeremy Forcec Duke University School of Medicine, Durham, NC, USA;d Duke Cancer Institute, Durham, NC, USAView further author information

&

Yara Abdoue UNC School of Medicine, Chapel Hill, NC, USAView further author information